Reconstitution of immune responses against Kaposi sarcoma-associated herpesvirus

AIDS

Volumn 24, Issue 14, 2010, Pages 2279-2281

  Flores, Roberto ^a   Goedert, James J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

combination antiretroviral therapy; HIV AIDS; Kaposi sarcoma associated herpes virus

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS ANTIBODY;

HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RECONSTITUTION; IMMUNE RESPONSE; KAPOSI SARCOMA; MALE HOMOSEXUAL; MORBIDITY; MORTALITY; NOTE; PRIORITY JOURNAL; VIREMIA; VIRUS CARCINOGENESIS; VIRUS REPLICATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBODY FORMATION; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HUMANS; SARCOMA, KAPOSI;

EID: 77956228929     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833c7bb8     Document Type: Note

References (31)

1. Clifford G, Polesel J, Rickenbach M, Maso L, Keiser O, Kofler A, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretro-viral therapy. J Natl Cancer Inst 2005; 97:425-432.
2. Sullivan S, Hirsch HH, Franceschi S, Steffen I, Boffiel-Amari E, Mueller NJ, et al. Kaposi sarcoma herpes virus antibody response and viraemia following highly active antiretroviral therapy in the Swiss HIV Cohort Study. AIDS 2010; 24:2245-2252.
3. Moore PS, Chang Y. Kaposi's sarcoma (KS), KS-associated herpesvirus, and the criteria for causality in the age of molecular biology. Am J Epidemiol 1998; 147:217-221.
4. Miller G, Heston L, Grogan E, Gradoville L, Rigsby M, Sun R, et al. Selective switch between latency and lytic replication of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. J Virol 1997; 71:314-324.
5. Ganem D. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest 2010; 120:939-949.
6. Schulz T. The pleiotropic effects of Kaposi's sarcoma herpes-virus. J Pathol 2006; 208:187-198.
7. Chen L, Lagunoff M. Establishment and maintenance of Kaposi's sarcoma-associated herpesvirus latency in B cells. J Virol 2005; 79:14383-14391.
8. Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995; 346:799-802.
9. Engels E, Whitby D, Goebel PB, Stossel A, Waters D, Pintus A, et al. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma. AIDS 2003; 17:1847-1851.
10. Campbell TB, Borok M, Gwanzura L, MaWhinney S, White IE, Ndemera B, et al. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS 2000; 14:2109-2116.
11. Cannon M, Dollard S, Black J, Edlin B, Hannah C, Hogan S, et al. Risk factors for Kaposi's sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. AIDS 2003; 17:215-222.
12. Pellet C, Chevret S, Blum L, Gauvill C, Hurault M, Blanchard G, et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J Invest Dermatol 2001; 117:858-863.
13. Gill J, Bourboulia D, Wilkinson J, Hayes P, Cope A, Marcelin AG, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002; 31:384-390.
14. Bourboulia D, Aldam D, Lagos D, Allen E, Williams I, Cornforth D, et al. Short-and long-term effects of highly active antire-troviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS 2004; 18:485-493.
15. Brown E, Whitby D, Vitale F, Marshall V, Mbisa G, Gamache C, et al. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. Cancer 2006; 107:2282-2290.
16. Biggar R, Engels E, Whitby D, Kedes D, Goedert J. Antibody reactivity to latent and lytic antigens to human herpesvirus-8 in longitudinally followed homosexual men. J Infect Dis 2003; 187:12-18.
17. Lane AS, Dollard S, Jaffe H, Offermann M, Spira T, Gunthel C, et al. Repeated measures study of human herpesvirus 8 (HHV-8) DNA and antibodiesin men seropositive for both HHV-8 and HIV. AIDS 2004; 18:1819-1826.
18. Kimball L, Casper C, Koelle D, Morrow R, Corey L, Vieira J. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. J Infect Dis 2004; 189:2016-2022.
19. Guihot A, Dupin N, Marcelin AG, Gorin I, Bedin AS, Bossi P, et al. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis 2006; 194:1078-1088.
20. Barozzi P, Bonini C, Potenza L, Masetti M, Cappelli G, Gruarin P, et al. Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. Transplantation 2008; 86:738-744.
21. Strickler HD, Goedert JJ, Bethke FR, Trubey CM, O'Brien TR, Palefsky J, et al. Human herpesvirus 8 cellular immune responses in homosexual men. J Infect Dis 1999; 180:1682-1685.
22. WilkinsonJ,CopeA,GillJ,BourbouliaD,HayesP,ImamiN,etal. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. J Virol 2002; 76:2634-2640.
23. Bihl F, Mosam A, Henry L, Chisholm J, Dollard S, Gumbi P, et al. Kaposi's sarcoma-associated herpesvirus-specific immune re-constitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma. AIDS 2007; 21:1245-1252.
24. Bihl F, Berger C, Chisholm J, Henry L, Bertisch B, Trojan A, et al. Cellular immune responses and disease control in acute AIDS-associated Kaposi's sarcoma. AIDS 2009; 23: 1918-1922.
25. Burbelo P, Leahy H, Groot S, Bishop L, Miley W, Iadarola M, et al. Four-antigen mixture containing v-cyclin for serological screening of human herpesvirus 8 infection. Clin Vaccine Immunol 2009; 16:621-627.
26. Burbelo P, Issa AT, Ching KH, Wyvill KM, Little RF, Iadarola MJ, et al. Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric castleman disease, and primary effusion lymphoma. J Infect Dis 2010 [Epub ahead of print].
27. Laney AS, Cannon M, Jaffe H, Offermann M, Ou CY, Radford K, et al. Human herpesvirus 8 presence and viral load are associated with the progression of AIDS-associated Kaposi's sarcoma. AIDS 2007; 21:1541-1545.
28. Areste C, Blackbourn D. Modulation of the immune system by Kaposi's sarcoma-associated herpesvirus. Trends Microbiol 2009; 17:119-129.
29. West J, Damania B. Kaposi's sarcoma-associated herpesvirus and innate immunity. Future Virol 2010; 5:185-196.
30. Liang C, Lee JS, Jung J. Immune evasion in Kaposi's sarcoma-associated herpes virus associated oncogenesis. Semin Cancer Biol 2008; 18:423-436.
31. Moore PS, Chang Y. Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin? Ann Rev Microbiol 2003; 57:609-639.